TG Therapeutics Inc. (TGTX)
TGTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$54.34
-1.68% on the day
Market cap
$8.3B
Mid cap
Revenue · 2025
$616.3M
+87.3% on 2024
Net income · 2025
$447.2M
72.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TGTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001001316 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $616.3M |
| Net income | $447.2M |
| Operating income | $123.3M |
| Net margin | 72.6% |
| Operating margin | 20.0% |
| Revenue growth | +87.3% |
| Cash | $79.1M |
| Total assets | $1.1B |
| P/E (computed) | 18.6× |
| P/S (computed) | 13.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3ASR | S-3ASR | 2025-08-08 |
| Latest annual report FORM 10-K | 10-K | 2026-02-27 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-05 |
| Latest current report FORM 8-K | 8-K | 2026-08-03 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.8% |
| 1 month | +2.6% |
| 3 months | -0.9% |
| Year to date | +82.6% |
| 1 year | +59.1% |
| From 52-week high | -7.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals Inc. | $58.13 | -4.28% | $8.2B |
| AXSM | Axsome Therapeutics Inc. | $156.32 | -5.83% | $8.2B |
| CYTK | Cytokinetics Incorporated | $61.62 | -1.86% | $8.6B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
| ABVX | Abivax SA | $86.22 | -0.83% | $7.5B |
| SYRE | Spyre Therapeutics Inc. | $80.45 | -6.34% | $7.1B |
| IONS | Ionis Pharmaceuticals Inc. | $42.38 | -2.95% | $7.0B |
| AMRX | Amneal Pharmaceuticals Inc. | $19.57 | -2.30% | $6.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier